BioCentury
ARTICLE | Clinical News

Ease of use results for Trimeris' T-20

July 11, 2001 7:00 AM UTC

TRMS reported that in a substudy of a Phase II trial of its T-20 viral fusion inhibitor in 55 patients with HIV/AIDS who had 48 weeks of treatment, self-administered daily subcutaneous injections of T...